Maravai LifeSciences Holdings

Youtube Subscribe

Open: 6.95 Close: 8.36 Change: 1.41

The 10 top things that an AI found about Maravai LifeSciences Holdings... they will surprise you

The game is changing. There is a new strategy to evaluate Maravai LifeSciences Holdings fundamental value, possible risks and most salient advantages. Investors have traditionally relied in reading large amounts of text to evaluate the fundamental value of a stock or company. However, the development of Artificial Intelligence (AI) tools is modifying the way investments are evaluated in markets. Today, machine learning, natural language processing and bigdata allow making this process automatic, reducing large amounts of text to the elements that have a higher activation in a neural network. We programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Maravai LifeSciences Holdings are: Holdings, Maravai, LifeSciences, Lifesciences, Analyst, …

Concept Map

Semantic Network

Stock Summary

Maravai LifeSciences Holdings, Inc. provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases. The Nucleic Acid Production segment manufactures and sells products for use.

Today's Summary

Shares of Maravai LifeSciences Holdings surged 65% to $8.41 after it reported a 64% fourth-quarter revenue decline. Revenues are forecast to shrink, but earnings are expected to improve. Maravai LifeSciences Holdings Inc shares had fallen by 19.7% this quarter. 12 West Capital Management - Joel Ramin - 13F Holdings - Marvai Lifesciences. Analyst consensus on Maravai Lifesciences Holdings is a Moderate Buy with an average price target of $11.50, representing a 125.05% upside. Analyst consensus is a moderate Buy with a target price of $10.50.

Today's News

Shares of Maravai LifeSciences Holdings surged 65% to $8.41 after it reported a 64% fourth-quarter revenue decline. Revenues are forecast to shrink, but earnings are expected to improve. Maravai LifeSciences Holdings Inc shares had fallen by 19.7% this quarter. 12 West Capital Management - Joel Ramin - 13F Holdings - Marvai Lifesciences. Analyst consensus on Maravai Lifesciences Holdings is a Moderate Buy with an average price target of $11.50, representing a 125.05% upside. Analyst consensus is a moderate Buy with a target price of $10.50.

Stock Profile

"Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, Viral Clearance Prediction kits, and custom services. It serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California."

Keywords

This document will help you to evaluate Maravai LifeSciences Holdings without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Maravai LifeSciences Holdings are: Holdings, Maravai, LifeSciences, Lifesciences, Analyst, consensus, Buy, and the most common words in the summary are: maravai, lifesciences, stock, holding, news, inc, report, . One of the sentences in the summary was: Revenues are forecast to shrink, but earnings are expected to improve. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #maravai #lifesciences #stock #holding #news #inc #report.

Read more →

Youtube Subscribe

---